Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1

Metastatic colorectal cancer (mCRC) patients have poor overall survival despite using irinotecan- or oxaliplatin-based chemotherapy combined with anti-EGFR (epidermal growth factor receptor) drugs, especially those with the oncogene mutation of KRAS. Metformin has been reported as a potentially nove...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Xie, Jinye, Xia, Liangping, Xiang, Wei, He, Wenzhuo, Yin, Haofan, Wang, Fang, Gao, Tianxiao, Qi, Weiwei, Yang, Zhonghan, Yang, Xia, Zhou, Ti, Gao, Guoquan
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2020
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7293710/
https://ncbi.nlm.nih.gov/pubmed/32444490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1918845117
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados